AYTU
Income statement / Annual
Last year (2024), Aytu BioPharma, Inc.'s total revenue was $81.00 M,
a decrease of 24.58% from the previous year.
In 2024, Aytu BioPharma, Inc.'s net income was -$15.84 M.
See Aytu BioPharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
| Operating Revenue |
$81.00 M
|
$107.40 M
|
$96.67 M
|
$65.63 M
|
$27.63 M
|
$7.32 M
|
$3.66 M
|
$3.22 M
|
$2.56 M
|
$261,782.00
|
| Cost of Revenue |
$26.42 M |
$40.77 M |
$44.39 M |
$36.43 M |
$7.55 M |
$2.20 M |
$2.05 M |
$1.42 M |
$957,076.00 |
$88,109.00 |
| Gross Profit |
$54.59 M |
$66.63 M |
$52.28 M |
$29.20 M |
$20.08 M |
$5.12 M |
$1.61 M |
$1.80 M |
$1.61 M |
$173,673.00 |
| Gross Profit Ratio |
0.67 |
0.62 |
0.54 |
0.44 |
0.73 |
0.7 |
0.44 |
0.56 |
0.63 |
0.66 |
| Research and Development
Expenses |
$2.79 M
|
$4.10 M
|
$14.44 M
|
$5.62 M
|
$1.72 M
|
$589,072.00
|
$167,595.00
|
$1.35 M
|
$6.32 M
|
$3.42 M
|
| General & Administrative
Expenses |
$22.51 M
|
$28.63 M
|
$31.17 M
|
$25.50 M
|
$19.66 M
|
$0.00
|
$17.73 M
|
$17.61 M
|
$8.83 M
|
$4.38 M
|
| Selling & Marketing
Expenses |
$26.96 M
|
$41.45 M
|
$38.71 M
|
$30.31 M
|
$11.40 M
|
$0.00
|
$0.00
|
-$242.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$49.47 M
|
$70.08 M
|
$69.88 M
|
$55.81 M
|
$34.80 M
|
$19.24 M
|
$17.73 M
|
$17.61 M
|
$8.83 M
|
$4.38 M
|
| Other Expenses |
$7.58 M |
-$4.78 M |
$4.07 M |
$6.01 M |
$4.49 M |
$2.14 M |
$6.28 M |
$1.71 M |
$664,707.00 |
$4,890.00 |
| Operating Expenses |
$59.84 M |
$78.96 M |
$88.39 M |
$67.44 M |
$41.01 M |
$21.96 M |
$19.45 M |
$20.66 M |
$15.81 M |
$7.81 M |
| Cost And Expenses |
$86.26 M |
$119.73 M |
$132.77 M |
$103.87 M |
$48.57 M |
$24.17 M |
$21.50 M |
$22.08 M |
$16.77 M |
$7.89 M |
| Interest Income |
$0.00 |
$9,000.00 |
$14,000.00 |
$6,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$4.79 M |
$0.00 |
$147.50 M |
$0.00 |
$0.00 |
$0.00 |
$749,423.00 |
$2.53 M |
$5.49 M |
$114,994.00 |
| Depreciation &
Amortization |
$8.27 M
|
$8.82 M
|
$10.15 M
|
$7.70 M
|
$4.59 M
|
$2.24 M
|
$1.85 M
|
$1.84 M
|
$874,789.00
|
$118,202.00
|
| EBITDA |
-$1.01 M
|
-$3.51 M
|
-$27.96 M
|
-$29.04 M
|
-$12.21 M
|
-$14.12 M
|
-$15.25 M
|
-$18.13 M
|
-$21.81 M
|
-$7.51 M
|
| EBITDA Ratio |
-0.01 |
-0.07 |
0.43 |
-0.22 |
-0.89 |
-0.6 |
-2.45 |
-4.5 |
-5.2 |
-28.7 |
| Operating Income Ratio
|
-0.06
|
-0.16
|
0.38
|
-0.58
|
-0.76
|
-2.3
|
-5.38
|
-6.25
|
-8.47
|
-29.16
|
| Total Other
Income/Expenses Net |
-$8.82 M
|
$14,000.00
|
$1.02 M
|
$840,000.00
|
$7.51 M
|
-$10.29 M
|
$9.51 M
|
-$2.38 M
|
-$6.48 M
|
-$114,994.00
|
| Income Before Tax |
-$14.08 M |
-$17.05 M |
-$110.28 M |
-$58.03 M |
-$13.62 M |
-$27.13 M |
-$10.19 M |
-$22.51 M |
-$28.18 M |
-$7.75 M |
| Income Before Tax Ratio
|
-0.17
|
-0.16
|
-1.14
|
-0.88
|
-0.49
|
-3.71
|
-2.78
|
-6.99
|
-11
|
-29.59
|
| Income Tax Expense |
$1.77 M |
-$57,000.00 |
-$110,000.00 |
$259,000.00 |
-$9.92 M |
$20.04 M |
-$2.13 M |
$1.11 M |
$8.48 M |
-$23,910.00 |
| Net Income |
-$15.84 M |
-$17.05 M |
-$108.78 M |
-$58.29 M |
-$13.62 M |
-$47.17 M |
-$10.19 M |
-$22.51 M |
-$28.18 M |
-$7.72 M |
| Net Income Ratio |
-0.2 |
-0.16 |
-1.14 |
-0.89 |
-0.13 |
-6.44 |
-2.78 |
-6.99 |
-11 |
-29.5 |
| EPS |
-2.86 |
-5.11 |
-74.01 |
-69.6 |
-60.2 |
-1210.28 |
-3061.23 |
-193194.38 |
-1294738.36 |
-551671.71 |
| EPS Diluted |
-2.86 |
-5.11 |
-74.01 |
-69.6 |
-60.2 |
-1210.28 |
-3061.23 |
-193194.38 |
-1294738.36 |
-551671.71 |
| Weighted Average Shares
Out |
$5.54 M
|
$3.34 M
|
$1.47 M
|
$840,000.00
|
$230,000.00
|
$38,972.00
|
$3,328.03
|
$116.51
|
$21.77
|
$14.00
|
| Weighted Average Shares
Out Diluted |
$5.54 M
|
$3.34 M
|
$1.47 M
|
$840,000.00
|
$230,000.00
|
$38,972.00
|
$3,328.03
|
$116.51
|
$21.77
|
$14.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
